nintedanib; vargatef (Ofev, BIBF-1120)
Jump to navigation
Jump to search
Indications
* on list of drugs to avoid; no survival benefit[3]
* slows progression of disease on pulmonary function tests[4]
* does not elevate patients' perceived quality of life,[4]
Contraindications
Dosage
Adverse effects
- diarrhea (common)
- nausea, vomiting
- abdominal pain
- hepatotoxicity[3]
- abnormal liver function tests
- anorexia
- headache
- weight loss
- hypertension
- risk of thromboembolism[3]
Mechanism of action
- tyrosine kinase inhibitor
- may attenuate lung-function decline & acute exacerbations in patients with idiopathic pulmonary fibrosis[1]
More general terms
References
- ↑ 1.0 1.1 Richeldi L et al Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. May 18, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24836310 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1402584
- ↑ FDA News Release. October 15, 2014 FDA approves Ofev to treat idiopathic pulmonary fibrosis http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm
- ↑ 3.0 3.1 3.2 3.3 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
- ↑ 4.0 4.1 4.2 Dempsey TM, Sangaralingham LR, Yao Xet al. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2019 Jul 15; 200:168 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31150266 https://www.atsjournals.org/doi/10.1164/rccm.201902-0456OC
- ↑ 5.0 5.1 FDA News Release. March 9, 2020 FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-group-progressive-interstitial-lung-diseases